AGN-195263

DRUG2 trials

Sponsors

Allergan

Conditions

Dry Eye Syndromes

Phase 3

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

TerminatedNCT02815293

AllerganDry Eye Syndromes

Start: 2016-09-30End: 2017-06-21Updated: 2019-02-19

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

TerminatedNCT02965846

AllerganDry Eye Syndromes

Start: 2016-12-13End: 2017-06-13Updated: 2018-11-30